Group 1 - The pharmaceutical sector continues to rise, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index increasing by 2.3% and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 1.6% [1] - The CSI Innovative Drug Industry Index, CSI Biotechnology Theme Index, and CSI 300 Pharmaceutical and Health Index all saw an increase of 0.4% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of nearly 30 million shares throughout the day [1] Group 2 - CITIC Securities points out that the competitiveness of China's pharmaceutical industry is continuously improving [1] - On the innovation front, national policies are actively encouraging industry innovation, and global liquidity improvements are beneficial for innovative drug companies' pricing [1] - In terms of international expansion, China possesses manufacturing and supply chain advantages, while its innovation capabilities are rapidly enhancing, leading to a long-term positive outlook for the pharmaceutical industry to develop global large companies [1]